MUDr. Petr Buček s.r.o.
- Address
- lock Available on a paid plan
MUDr. Petr Buček s.r.o. - Chronic Kidney Disease & Hypertension Research
MUDr. Petr Buček s.r.o. is a clinical research facility specializing in cardiorenal medicine, with particular emphasis on the intersection of chronic kidney disease (CKD) and hypertension. The center focuses on evaluating innovative pharmacological interventions designed to slow disease progression and improve outcomes in patients with complex metabolic and cardiovascular conditions.
- Chronic kidney disease progression and renal function preservation
- Hypertension management in patients with renal impairment
- Novel combination therapies for cardiorenal protection
The research center is actively engaged in advanced clinical trials assessing the efficacy of novel therapeutic combinations, including studies evaluating changes in estimated glomerular filtration rate (eGFR) as a key endpoint for CKD progression. The facility's expertise encompasses comprehensive evaluation of both efficacy and safety profiles of emerging treatments in this challenging patient population.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1AstraZeneca AB1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 634 other sites in Czechia
Therapeutic Area Benchmark — Czechia
Select a therapeutic area to compare against other sites in Czechia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Czechia
Market Share
Country: Czechia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in MUDr. Petr Buček s.r.o.
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety of Baxdrostat and Dapagliflozin on Renal and Cardiovascular Outcomes in Chronic Kidney Disease with Hypertension | AstraZeneca AB | Phase III | Recruiting | May 2025 | — |
IMP list
lock Showing 1 of 3 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Baxdrostat | 2 | Unknown | 2024-06-05 | 2025-05-07 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.